The Safe Baby Formula Act of 2025 requires the Secretary of Health and Human Services to study the health impacts of arsenic, cadmium, mercury, and lead in infant formula. The study must be completed within one year of enactment and, separately, the bill directs HHS to establish standards for regulating these metals.
Those standards can take the form of enforcement action levels or, through rulemaking, maximum contamination levels. The act ties the term “infant formula” to the definition used in the Federal Food, Drug, and Cosmetic Act, ensuring regulatory alignment with existing law.
At a Glance
What It Does
Not later than 1 year after enactment, HHS must complete a study on the health impacts of arsenic, cadmium, mercury, and lead in infant formula. Not later than 90 days after enactment, HHS must establish enforcement action levels or, through rulemaking, maximum contamination levels for these metals.
Who It Affects
Infant formula manufacturers and importers, federal regulators at HHS and FDA, healthcare providers who advise caregivers, and parents relying on formula for infants.
Why It Matters
It creates a data-driven pathway to reduce toxic metal exposure in infants and to establish clear regulatory standards that can be enforced over time.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill starts by demanding a rigorous study of how four toxic metals—arsenic, cadmium, mercury, and lead—affect infant health when present in formula. The study’s findings would inform future regulatory decisions and help identify safe exposure levels for infants.
In parallel, the act instructs HHS to set standards for regulating these metals. There are two possible implementation routes: HHS can issue enforcement action levels that trigger agency responses for noncompliant products, or it can complete rulemaking to set maximum permissible levels for these metals in infant formula.
The act anchors its regulatory scope to a definition of “infant formula” that aligns with existing FDA definitions, ensuring consistency with current law. Overall, the bill pairs an evidence-gathering step with a regulatory pathway to translate findings into enforceable protections for infants.
The Five Things You Need to Know
HHS must complete a study on arsenic, cadmium, mercury, and lead in infant formula within one year.
Within 90 days of enactment, HHS must establish enforcement action levels or maximum contaminant levels via rulemaking for the four metals.
The term "infant formula" is defined by the FDA’s current FD&C Act definition (section 201(z)).
The act does not itself set numeric limits in the statute but authorizes two regulatory pathways to establish them.
Standards focus narrowly on four heavy metals and apply through HHS and FDA regulatory processes.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short Title
This section provides the formal citation for the act as the “Safe Baby Formula Act of 2025,” creating a named framework for the bill’s provisions and future reference.
Study on the metals in infant formula
This section requires the Secretary of Health and Human Services to complete a study within one year after enactment on the health impacts of arsenic, cadmium, mercury, and lead in infant formula. The study should assess exposure pathways, potential health outcomes, and risk levels to inform subsequent regulatory action.
Prohibition of toxic metals in infant formula
This section mandates action within 90 days of enactment. It requires the Secretary to establish either enforcement action levels for the four metals or, through rulemaking, maximum contamination levels for those metals in infant formula. This creates a concrete regulatory pathway to address toxic metals in formula based on the study results and risk assessment.
Definition
This section ties the term “infant formula” to the meaning used in section 201(z) of the Federal Food, Drug, and Cosmetic Act, ensuring that the act’s scope aligns with established FDA definitions and regulatory language.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Infants and their families, who gain protection from regulated exposure to toxic metals in formula.
- Pediatric health professionals and researchers, who gain clearer data and guidance for risk assessment and patient counseling.
- Public health agencies, which obtain a defined framework and metrics to monitor and improve infant safety.
- Manufacturers that proactively align products to forthcoming standards, achieving clearer compliance pathways.
- Consumers and safety advocates who benefit from transparency and standardized protections.
Who Bears the Cost
- Infant formula manufacturers and importers, due to compliance investments and potential reformulation to meet new standards.
- FDA and HHS agencies, which face additional workload in studying, monitoring, and enforcing standards.
- Retailers and distributors, who may need enhanced testing and verification processes to ensure product safety.
- Small producers that may face higher relative costs to meet standards and updates to testing regimes.
Key Issues
The Core Tension
The central tension is between acting quickly to reduce exposure through enforcement actions versus awaiting formal rulemaking to establish numeric limits. Quick action can protect infants sooner but may later require adjustments if rulemaking yields different limits, while slower rulemaking could delay protections in practice.
The bill creates a dual-track approach to metals regulation: it requires a focused, science-based study within a year and authorizes a move to enforceable standards within a short regulatory clock. The two implementation paths—enforcement action levels or formal rulemaking—allow regulators to respond quickly if a metals risk is identified, while also enabling more precise limits through formal rulemaking if needed.
This structure invites careful attention to how data from the study translates into practical standards and how enforcement actions align with future rulemaking timelines. In practice, manufacturers will need to anticipate both possibilities and invest in testing and quality controls to stay compliant when the standards are finally set.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.